Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Patent
1996-10-28
1999-02-02
Dodson, Shelley A.
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
424600, 424617, 424646, 424650, 424677, 424715, 424718, 424722, A61K 3332
Patent
active
058661689
ABSTRACT:
Dermatological/pharmaceutical compositions, well suited for the therapeutic treatment of and/or alleviation of pain associated with at least one of the skin disorders, zona, poszoster, scald or burns, demodicidosis, skin ulcer, fibrosis, hypertrophic cicatrization and/or acne rosacea, comprise an effective substance P antagonist amount of at least one salt of yttrium, lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, tin, zinc, manganese, cobalt, barium, strontium, or mixture thereof, in a dermatologically/pharmaceutically acceptable medium therefor.
REFERENCES:
patent: 3519711 (1970-07-01), Svigals
patent: 3772431 (1973-11-01), Mlkvy et al.
patent: 3888976 (1975-06-01), Mlkvy et al.
patent: 4477439 (1984-10-01), D'Alelio
patent: 4711780 (1987-12-01), Fahim
patent: 4735802 (1988-04-01), Le
patent: 4943432 (1990-07-01), Biener
patent: 4980184 (1990-12-01), Gordon
patent: 4986981 (1991-01-01), Glace et al.
patent: 5047409 (1991-09-01), Di Schiena et al.
patent: 5079010 (1992-01-01), Natterer
patent: 5091171 (1992-02-01), Yu et al.
patent: 5132119 (1992-07-01), Lee
patent: 5202130 (1993-04-01), Grant et al.
patent: 5296476 (1994-03-01), Henderson
patent: 5593992 (1997-01-01), Adams et al.
patent: 5716625 (1998-02-01), Hahn et al.
Maison G. deNavarre, The Chemistry and Manufacture of Cosmetics, 2nd Ed. vol. IV, p. 1261 (1975).
Alexander A. Fisher, "Irritant Reactions from Topical Urea Preparations Used for Dry Skin Advantages of a Urea-Free `Dead Sea Salt` Cream", Current Contact News, vol. 18, pp.761-772 (1976).
The United States Pharmacopeia, "Alumina/Drug Substances and Dosage Form", pp. 20 and 22 (1975).
Nordia Briefs, "A Salt-Containing Cream for Dry Skin", No. 484, Jan. 1978.
Cosmetic Counter, vol. 109, Oct. 1994.
Jancso-Gabor, "Action of rare earth metal complexes on neurogenic as well as on bradykinin-induced inflammation", J. Pharm. Pharmac., 22:366-371 (1970).
"La peau sensible, un authentique syndrome clinique", Le Quotidien du Medecin, No. 5747, Dec. 6, 1995; Cosmetologie, Therapeutique, No. 1511, Dec. 17, 1995.
Uy Dong Sohn et al, "Agonist-Independent, Muscle-Type-Specific Signal Transduction Pathways in Cat Esophageal and Lower Esophageal Sphincter Circular Smooth Muscle", J. of Pharmacology & Experimental Therapeutics,273:481-491 (1995).
Mitsuo Ishizawa, "Contractile Responses of Longitudinal Muscle Strip to 5-HT and Influences of Divalent Cations in the Guinea-Pig Isolated Colon", J. Smooth Muscle Res., 30:65-72 (1994).
H. Goodman, Cosmetic Dermatology, First Edition, Fourth Impression, p. 181 (1936).
Martindale, The Extra Pharmacopoeia, Twenty-seventh Edition, The Pharmaceutical Press, London, pp. 219, 1775 and 1814 (1977).
McGraw-Hill Dictionary of Scientific and Technical Terms, Fifth Edition, pp. 109 and 332.
Sohn et al, Different Receptors Activate a Different Single G-Protein in Esophageal. (Gis) and in LES (Gq) Circular Smooth Muscle, Gastroenterology, vol. 104 (1993).
S.M. Moussaoui et al, Br. J. Pharmacol., "A non-peptide NK.sub.1 -receptor antagonist, RP 67580, inhibits neurogenic inflammation postsynaptically", vol. 109, No.1, 1993, pp. 259-265.
J. Wallengren, Br. J. Dermatol., "Substance P antagonist inhibits immediate and delayed type cutaneous hypersensitivity reactions", vol. 124, No. 4, 1991, pp. 324-328.
J. Wallengren et al, Contact Dermatitis, "Some neuropeptides as modulators of experimental contact allergy", vol. 19, No. 5, 1988, pp. 351-354.
T. Lotti et al, J. Am. Acad. Dermatol., "Treatment of aquagenic pruritus with topical capsaicin cream", vol. 30, No. 2PT1, Feb. 1994, pp. 232-235.
T. Sakurada et al, Brain Res., "A selective and extremely potent antagonist of the neurokinin-1 receptor", vol. 593, No. 2, 1992, pp. 319-322.
K. Folkers et al, Proc. Natl. Acad. Sci. USA, "Spantide II, an effective tachykinin antagonist having high potency",vol. 87, No. 12, 1990, pp. 4833-4855.
Rajadhyaksha, Chemical Abstracts, vol. 107, #223281 (1987).
DiSchiena, Chemical Abstracts, vol. 106, #107768 (1987).
Smith et al, Chemical Abstract, vol. 114, #206554 (1991).
Dufetal et al, Chemical Abstracts, vol. 116, #135998 (1992).
British Medical Journal (England), vol. 4, Nov. 1975, p. 264.
Chemical Abstracts, vol. 122, No. 16, Apr. 1995, Columbus, Ohio, abstract No. 196540.
Chemical Abstracts, vol. 95, No. 22, Nov. 1981, Columbus, Ohio, abstract No. 192217.
Chemical Abstracts, vol. 120, No. 17, Apr. 1994, Columbus, Ohio, abstract No. 210122.
Breton Lionel
De Lacharriere Olivier
Dodson Shelley A.
Societe l'Oreal S.A.
Williamson Michael A.
LandOfFree
Dermatological/pharmaceutical compositions comprising lanthanide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dermatological/pharmaceutical compositions comprising lanthanide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dermatological/pharmaceutical compositions comprising lanthanide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1114844